TARGETING EPSTEIN BARR VIRUS ASSOCIATED GLYCOPROTEIN BALF-4 INTERACTIONS WITH O. sanctum BIO COMPOUNDS | PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY

Introduction: EBV associated with oncogenic transformations of B cells is also associated with a strong BALF-4 glycoprotein and may be a good candidate for new natural antiviral compounds. Thus the goal of the current study is to investigate the inhibitory ability of O. Bioactive compounds of the sanctum against BALF-4 of EBV.

Materials and methods: With further optimization of both the protein and ligands, the 3D structure of BALF-4 was recovered from the PDB data bank. The in-silico inhibitory potential of the selected BALF-4 beta lactam derivatives was achieved by AutoDock 2.0 and visualised with PYMOL using molinspiration calculations to determine the molecular properties of BALF-4 derivatives and further evaluation of their drug likeliness.

Results: The potent inhibitor drug for targeting BALF-4 with a promising binding energy of -9.32 and -8.12 Kcal/mol with four bonds of hydrogen appears to be cirsimaritin and ursolic acid. Drug likeliness parameters, followed by other biocompounds, recorded ursolic acid as a promising protease and enzyme inhibitor.

Conclusion: The study results highlight the promising inhibitory impact of O.sanctum biocompounds on BALF-4 and indicate that BALF-4 is the best target for the treatment of EBV infections with more in-vivo validation aimed at it.

Please see the link :- https://www.ikprress.org/index.php/PCBMB/article/view/5297